Boston Partners Boosts Position in Evolent Health, Inc. (NYSE:EVH)

Boston Partners grew its holdings in shares of Evolent Health, Inc. (NYSE:EVH) by 92.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,444,006 shares of the technology company’s stock after buying an additional 1,171,304 shares during the period. Boston Partners owned 2.10% of Evolent Health worth $27,097,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. R Squared Ltd purchased a new stake in Evolent Health in the fourth quarter worth $31,000. AlphaQuest LLC grew its stake in Evolent Health by 21,650.0% in the fourth quarter. AlphaQuest LLC now owns 3,045 shares of the technology company’s stock worth $34,000 after purchasing an additional 3,031 shares during the period. Parkside Financial Bank & Trust grew its stake in Evolent Health by 90.7% in the fourth quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company’s stock worth $56,000 after purchasing an additional 2,358 shares during the period. AlphaCentric Advisors LLC purchased a new stake in Evolent Health in the fourth quarter worth $61,000. Finally, KBC Group NV grew its stake in Evolent Health by 124.6% in the fourth quarter. KBC Group NV now owns 6,741 shares of the technology company’s stock worth $76,000 after purchasing an additional 3,739 shares during the period.

Evolent Health Trading Down 0.1 %

Shares of NYSE:EVH opened at $10.13 on Thursday. Evolent Health, Inc. has a 1 year low of $8.35 and a 1 year high of $33.63. The stock’s fifty day moving average price is $10.04 and its 200-day moving average price is $16.47. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. The company has a market cap of $1.18 billion, a P/E ratio of -12.35 and a beta of 1.49.

Evolent Health (NYSE:EVH) last posted its earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.35). Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. The firm had revenue of $646.54 million during the quarter, compared to the consensus estimate of $650.92 million. Sell-side analysts expect that Evolent Health, Inc. will post 0.08 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price target on shares of Evolent Health in a research note on Friday, February 21st. Piper Sandler reissued an “overweight” rating and issued a $16.00 target price (down from $17.00) on shares of Evolent Health in a research note on Friday, February 21st. Oppenheimer cut their target price on Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday, January 24th. JPMorgan Chase & Co. cut their target price on Evolent Health from $13.00 to $12.00 and set an “overweight” rating on the stock in a research note on Monday, March 10th. Finally, BTIG Research cut their target price on Evolent Health from $36.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Evolent Health has a consensus rating of “Buy” and a consensus price target of $17.71.

Insider Buying and Selling at Evolent Health

In related news, President Daniel Joseph Mccarthy purchased 11,040 shares of Evolent Health stock in a transaction on Thursday, March 6th. The stock was acquired at an average price of $9.01 per share, for a total transaction of $99,470.40. Following the completion of the transaction, the president now directly owns 389,004 shares in the company, valued at $3,504,926.04. This represents a 2.92 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Diane Holder purchased 2,735 shares of Evolent Health stock in a transaction on Thursday, March 6th. The stock was bought at an average price of $9.33 per share, with a total value of $25,517.55. Following the transaction, the director now owns 70,584 shares of the company’s stock, valued at approximately $658,548.72. This represents a 4.03 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 74,000 shares of company stock valued at $666,315. 1.60% of the stock is owned by company insiders.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.